Loading
Colorectal Cancer Surgical Treatments / Advanced Radiotherapy Techniques / Colorectal and Anal Carcinomas · Review
Journal of Surgical Research · August 10, 2026
Well-designed and adequately powered for the question it asks.
This meta-analysis of 13 studies (3 RCTs, 10 observational) found that neoadjuvant radiation therapy does not significantly improve overall survival in upper rectal cancer (RR 0.92, 95% CI 0.83–1.02) but does significantly reduce local recurrence risk (RR 0.63, 95% CI 0.43–0.95). The evidence supports selective rather than routine use of NRT in higher-risk upper rectal cancers, with consideration of toxicity and anatomical factors.
Systematic review and meta-analysis of randomized controlled trials and observational studies. Studies of upper rectal cancer patients comparing neoadjuvant radiation therapy to upfront surgery; published from 2002 onward to reflect contemporary treatment paradigms. Intervention: Neoadjuvant radiation therapy. Compared with: Upfront surgery.
No statistically significant improvement in overall survival with NRT versus upfront surgery (risk ratio 0.92, 95% CI 0.83–1.02) Significant reduction in local recurrence risk with NRT (risk ratio 0.63, 95% CI 0.43–0.95) Analysis included 13 studies: 3 randomized controlled trials and 10 observational studies published from 2002 onward
Specific adverse effects of NRT compared to upfront surgery not reported in the abstract
Clinicians should consider selective rather than routine neoadjuvant radiation for upper rectal cancer, reserving it for higher-risk patients where local recurrence reduction may outweigh toxicity; overall survival is not improved. This represents a shift from the standard approach in lower and middle rectal cancers.
A rigorous meta-analysis of 13 studies (including 3 RCTs) with clear primary outcomes and adequate pooling; no overall survival benefit but significant local recurrence reduction supports selective rather than routine use in upper rectal cancer.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider selective rather than routine neoadjuvant radiation for upper rectal cancer, reserving it for higher-risk patients where local recurrence reduction may outweigh toxicity; overall survival is not improved. This represents a shift from the standard approach in lower and middle rectal cancers.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction Neoadjuvant radiation therapy (NRT) is a cornerstone in the treatment of lower and middle rectal cancers. However, the efficacy of NRT in upper rectal cancer remains debated due to conflicting recommendations and study outcomes. This study aims to re-evaluate the effects of NRT versus upfront surgery in upper rectal cancer through a comprehensive systematic review and meta-analysis of recent and relevant studies. Methods A systematic search was conducted in Ovid Medline, PubMed, Embase, Scopus, Cochrane Central, and Clinicaltrials.gov, filtering studies published from January 2002 onward to reflect contemporary treatment paradigms. We included randomized controlled trials and observational studies comparing outcomes between NRT and upfront surgery in upper rectal cancer. The primary outcomes were overall survival (OS) and local recurrence (LR). Results Thirteen studies met the inclusion criteria, comprising three randomized controlled trials and ten observational studies. Meta-analysis showed no statistically significant improvement in OS with NRT (risk ratio: 0.92, 95% confidence interval, 0.83-1.02), but a significant reduction in LR risk (risk ratio: 0.63, 95% confidence interval, 0.43-0.95). Conclusions NRT does not significantly improve OS for upper rectal cancer patients but can reduce the risk of LR in select patients. These findings suggest a selective use of NRT in higher risk upper rectal cancers, especially considering potential adverse effects and the anatomical challenges in defining upper rectal cancer. The analysis was limited by the heterogeneity of study designs and the retrospective nature of most included studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.